SERA SERA PROGNOSTICS, INC.
Services-Medical Laboratories · Nasdaq · SEC CIK 1534969 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1.1%
TTM net income YoY-2.6%
TTM EPS YoY11.8%
Revenue 3-yr CAGR-33.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-38,755.2%
Net margin-34,866.7%
FCF margin-30,199.0%
EBITDA margin-37,922.9%
Returns
ROE-49.7%
ROA-35.6%
ROIC (approx.)-46.5%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets34.4%
Debt / equity0.00x
Current ratio1.88x
Interest coverage-5,315.00x
Cash quality & payout
Operating cash flow / net income0.85x
Accruals ratio-5.3%
Payout ratio—
Capex / revenue508.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $81,000 | $77,000 | $306,000 | $268,000 | $82,000 |
| Cost of revenue | $164,000 | $82,000 | $210,000 | — | — |
| Gross profit | -$83,000 | -$5,000 | $96,000 | — | — |
| R&D expense | $13.17M | $14.73M | $15.22M | $14.24M | $11.02M |
| SG&A expense | $16.70M | $16.13M | $16.34M | $16.78M | $14.09M |
| Operating income | -$36.50M | -$36.63M | -$39.82M | -$45.65M | -$35.40M |
| Interest expense | $9,000 | $28,000 | $55,000 | — | — |
| Pretax income | -$31.93M | -$32.90M | — | — | — |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$31.93M | -$32.90M | -$36.24M | -$44.19M | -$35.01M |
| EBITDA | -$35.56M | -$35.80M | -$38.92M | -$44.90M | -$34.74M |
| EPS (basic) | -0.67 | -0.99 | -1.16 | -1.43 | -2.33 |
| EPS (diluted) | -0.67 | -0.99 | -1.16 | -1.43 | -2.33 |
| Weighted avg. shares (diluted) | 47.66M | 33.16M | 31.20M | 30.94M | 15.00M |
| Balance sheet | |||||
| Cash & equivalents | $3.94M | $4.04M | $3.88M | $29.88M | $58.93M |
| Short-term investments | $35.26M | $42.19M | $45.20M | $52.83M | $46.18M |
| Receivables | $12,000 | $34,000 | $160,000 | $113,000 | $27,000 |
| Current assets | $40.77M | $47.60M | $61.34M | $90.12M | $110.25M |
| PP&E, net | $1.15M | $1.24M | $2.00M | $3.06M | $1.77M |
| Intangibles | $910,000 | $1.03M | $0 | — | — |
| Total assets | $101.93M | $72.58M | $95.44M | $116.33M | $147.03M |
| Current liabilities | $24.19M | $24.77M | $24.44M | $15.54M | $8.41M |
| Total liabilities | $26.52M | $24.77M | $25.28M | $17.39M | $8.46M |
| Shareholders' equity | $75.41M | $47.80M | $70.16M | $98.94M | $138.56M |
| Cash flow statement | |||||
| Operating cash flow | -$25.62M | -$14.19M | -$27.19M | -$34.61M | -$31.64M |
| Capital expenditure | $726,000 | $56,000 | $128,000 | $791,000 | $1.30M |
| Free cash flow | -$26.35M | -$14.24M | -$27.32M | -$35.40M | -$32.94M |
| Investing cash flow | -$28.50M | $11.74M | $438,000 | $5.55M | -$82.56M |
| Financing cash flow | $54.03M | $2.61M | $752,000 | $5,000 | $159.59M |
| Depreciation & amortization | $940,000 | $833,000 | $900,000 | $756,000 | $659,000 |
| Stock-based compensation | $5.11M | $7.01M | $5.27M | $5.05M | $3.13M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.